In an attempt to identify transcription factors which activate sterol-regulatory element-binding protein 1c (SREBP-1c) transcription, we screened an expression cDNA library from adipose tissue of SREBP-1 knockout mice using a reporter gene containing the 2.6-kb mouse SREBP-1 gene promoter. We cloned and identified the oxysterol receptors liver X receptor (LXR␣) and LXR␤ as strong activators of the mouse SREBP-1c promoter. Sterol-regulatory element (SRE)-binding proteins (SREBPs) are transcription factors which belong to the basic helix-loophelix leucine zipper family (3-5). In contrast to other members of this family, SREBPs are synthesized as precursor proteins which remain bound to the endoplasmic reticulum and the nuclear envelope in the presence of sufficient sterol concentrations. Upon sterol deprivation, the precursor protein undergoes a sequential two-step cleavage process to release the NH 2 -terminal portion (28). This mature SREBP then enters the nucleus and activates the transcription of genes involved in cholesterol and fatty acid synthesis by binding to SREs or to palindromic sequences called E boxes within their promoter regions (20, 39). Three forms of SREBP have been characterized: SREBP-1a and -1c (also known as ADD1) (14, 38, 43) and SREBP-2. It has been shown that all of the cultured cells analyzed to date express primarily SREBP-2 and the SREBP1a isoform, whereas most organs, including the liver and adipose tissue, express predominantly SREBP-2 and the SREBP1c isoform (36). SREBP-1a is a stronger activator than SREBP-1c due to its longer transactivation domain and has a wider range of target genes involved in both cholesterol and fatty acid synthesis (30, 31).
Sterol-regulatory element (SRE)-binding proteins (SREBPs) are transcription factors which belong to the basic helix-loophelix leucine zipper family (3) (4) (5) . In contrast to other members of this family, SREBPs are synthesized as precursor proteins which remain bound to the endoplasmic reticulum and the nuclear envelope in the presence of sufficient sterol concentrations. Upon sterol deprivation, the precursor protein undergoes a sequential two-step cleavage process to release the NH 2 -terminal portion (28) . This mature SREBP then enters the nucleus and activates the transcription of genes involved in cholesterol and fatty acid synthesis by binding to SREs or to palindromic sequences called E boxes within their promoter regions (20, 39) . Three forms of SREBP have been characterized: SREBP-1a and -1c (also known as ADD1) (14, 38, 43) and SREBP-2. It has been shown that all of the cultured cells analyzed to date express primarily SREBP-2 and the SREBP1a isoform, whereas most organs, including the liver and adipose tissue, express predominantly SREBP-2 and the SREBP1c isoform (36) . SREBP-1a is a stronger activator than SREBP-1c due to its longer transactivation domain and has a wider range of target genes involved in both cholesterol and fatty acid synthesis (30, 31) .
Lipogenic enzymes, which are involved in energy storage through synthesis of fatty acids and triglycerides, are coordinately regulated at the transcriptional level during different metabolic states (9, 11) . Recent in vivo studies demonstrated that SREBP-1c plays a crucial role in the dietary regulation of most hepatic lipogenic genes, whereas SREBP-2 is actively involved in the transcription of cholesterogenic enzymes (13) . These include studies of the effects of the absence or overexpression of SREBP-1 on hepatic lipogenic gene expression (30, 31, 33) , as well as physiological changes of SREBP-1c protein in normal mice after dietary manipulation such as placement on high-carbohydrate diets, polyunsaturated fatty acid-enriched diets, and fasting-refeeding regimens (12, 17, 37, 40, 41) . The similar coordinated changes in SREBP-1c and lipogenic gene expression upon fasting and refeeding were also observed in adipose tissue (18) . In fat tissue, SREBP-1c (ADD1) appears to be involved in adipocyte differentiation and insulin resistance (19, 35) . Recent studies suggest that insulin or insulin-facilitated glucose uptake mediates lipogenesis through SREBP-1c induction (7, 8, 10, 21, 34) . Previous reports on the regulation of SREBP-1c have all demonstrated the induction to be at the mRNA level. Up-regulation of hepatic SREBP-1 mRNA was observed in the livers of rodents on a fastingrefeeding regimen or a chronic high-carbohydrate diet and in primary hepatocytes with a high-glucose medium (8, 10, 12, 41) . In contrast, down-regulation of SREBP-1c was observed in livers from fasted rodents, from insulin-depleted diabetic rats with streptozotocin treatment, and from mice on a diet containing polyunsaturated fatty acids (12, 17, 34, 37, 40, 41) .
In contrast to SREBP-2, which mediates sterol regulation completely at the cleavage level through interaction with SREBP cleavage-activating protein (SCAP) and site 1 protease, SREBP1c controls the transcriptional regulation of lipogenic enzymes by self-regulating the nuclear concentration of its mature form, which is highly correlated to its precursor and mRNA levels. The initial analysis of the mouse SREBP-1c promoter identified two functional regions (1) . One region is the SRE complex, which confers a response to SREBPs. Upstream of this region is an oxysterol-inducible region, the details of which remain unknown. To investigate the relationship between the promoter sequence and physiological regulation of SREBP-1c, we sought to identify transcription factors that might regulate the SREBP-1c promoter. In the screening of the SREBP-1c gene activators, we cloned and identified liver X receptors (LXR␣ [NR1H3] and LXR␤ [NR1H2]) as strong activators of SREBP-1c gene promoter.
LXRs belong to a subclass of nuclear hormone receptors that form obligate heterodimers with retinoid X receptors (RXRs) and are bound and activated by oxysterols (16, 22, 24, 27) . LXRs regulate the expression of cholesterol 7␣-hydroxylase, the rate-limiting enzyme of the classic bile acid biosynthetic pathway (22, 25, 27) ; cholesterol ester transfer protein, which translocates cholesterol ester between lipoprotein fractions (23); and ATP-binding cassette transporter 1 (ABC1), which modulates the reverse cholesterol transport from peripheral tissues and cholesterol absorption in the intestine (26) . Thus, LXR-RXR heterodimers serve as key regulators of cholesterol homeostasis. Identification of LXR-RXR as an activator of the SREBP-1c promoter reveals a new aspect of cholesterol and fatty acid metabolism.
MATERIALS AND METHODS
Materials and general methods. We obtained cholesterol, 22(R)-hydroxycholesterol [22(R)-HC], 25-hydroxycholesterol (25-HC), and 9-cis-retinoic acid (9CRA) from Sigma; Redivue [␣- 32 P]dCTP (6,000 Ci/mmol) from Amersham Pharmacia; restriction enzymes from New England BioLabs; and polyclonal antibodies against mouse LXR␣ and -␤ (C19, sc-6063x) and RXR␣ (D-20, sc-553x) from Santa Cruz Biotechnology, Inc.
Standard molecular biology techniques were used. DNA sequencing was performed with the PRISM dye terminator cycle sequencing kit and an ABI PRISM 310 genetic analyzer (Applied Biosystems).
Plasmids. Luciferase gene constructs containing 2.6-kb and 550-bp fragments of the mouse SREBP-1c promoter (pBP1c2600-Luc and pBP1c550-Luc, respectively) were prepared as described previously (1) . Human RXR␣ expression plasmid pRXR was a kind gift from D. J. Mangelsdorf. Other SREBP-1 promoter-luciferase constructs were produced by PCR using pBP1c550-Luc as a DNA template and subcloning the PCR products into the pGL2 basic or pGL2 promoter vector (Promega). The PCR primers used were as follows: 5Ј primers BP1c408-Luc (5Ј-GGCCAGGAGTGGGTAAA-3Ј), BP1c357-Luc (5Ј-GTGTG CGAACGAACCAG-3Ј), BP1c296-Luc (5Ј-GGATTCCGGACCCAGGCT-3Ј), BP1c249-Luc (5Ј-GGGTTGGGACGACAGTGA-3Ј), BP1c197-Luc (5Ј-GGC GCAGACGCGGTTA-3Ј), BP1c148-Luc (5Ј-GGGAGAAACCCGAGCT-3Ј), BP1c186-Luc (5Ј-GGACGCCCGCTAGTAACC-3Ј), BP1cLXREa-Luc (5Ј-GA CAGTGACCGCCAGTAACCC-3Ј), and BP1cLXREaM-Luc (5Ј-GACAGAGT CCGCCAGAATCCC-3Ј) and 3Ј primers BP1c41-Luc (5Ј-TAAGAGCTCGGT ACCTCCCCTAGGGC-3Ј), BP1c149-Luc (5Ј-GGTGCTCTGAATGGGGC-3Ј), BP1cLXREb-Luc (5Ј-CCGGGGTTACTAGCGGGC-3Ј), and BP1cLXREbM-Luc (5Ј-CCGGGGATTCTAGCGGGC-3Ј). The primers were tailed with an SmaI site (5Ј primers) and a KpnI site (3Ј primers).
Preparation of expression library and screening of transactivator of the SREBP-1c promoter. For preparation of the cytomegalovirus (CMV) promoterexpression vector, the SmaI site of CMV7 (2) was converted to a NotI site using a NotI linker and designated CMV7-NotI. Total RNA was extracted from adipose tissues from three SREBP-1 knockout mice (33) using Trizol (Life Technologies, Inc.). Poly(A) ϩ RNA was prepared from total RNA by two cycles of chromatography on oligo(dT) (mRNA Purification Kit; Amersham Pharmacia Biotech). A size-fractionated, directional cDNA library with SalI and NotI cohesive ends at the 5Ј and 3Ј termini, respectively, was constructed from 5 g of poly(A) ϩ RNA using a Superscript Plasmid Kit (Life Technologies, Inc.). Sizefractionated cDNA (Ͼ1.0 kb) was ligated with expression vector pCMV7-NotI using the protocol and reagents supplied with the Superscript kit. The ligation reaction of cDNAs and the vectors digested with SalI and NotI was transformed into electrocompetent DH5␣ cells and aliquoted into subpools containing approximately 1,500 clones. The transcriptional activity of each pool (1.5 to 2.0 g of total DNA) for the SREBP-1c promoter was assayed by transfection into human embryonic kidney (HEK) 293 cells with pBP1c2600-Luc (0.25 g) and control ␤-galactosidase reference plasmid pCMV-␤gal (0.1 g; Promega) as described below.
Transfections and luciferase assays. HEK 293 and HepG2 cells were grown at 37°C in an atmosphere of 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM) containing 25 mM glucose, 100 U of penicillin per ml, and 100 g of streptomycin sulfate per ml supplemented with 10% fetal calf serum (FCS). Transfection studies were carried out with cells plated on 12-well plates as described previously (1) . The indicated amount of each expression plasmid was transfected simultaneously with a luciferase reporter plasmid (0.25 g) and pCMV-␤gal or pSV-␤gal (0.1 to 0.4 g). The total amount of DNA in each transfection was adjusted to 1.5 g/well with pCMV7-NotI vector DNA. Ligands for LXR and RXR were dissolved in ethanol and added to cells after transfection in DMEM with 10% FCS. For suppressed conditions, DMEM with 10% FCS, cholesterol (10 g/ml), and 25-HC (1 g/ml) was used to suppress endogenous SREBP activity. The amount of luciferase activity in transfectants was measured and normalized to the amount of ␤-galactosidase activity as measured by standard kits (Promega).
Gel mobility shift assays. Gel mobility shift assays were done as previously described (1) . Briefly, nuclear extracts were prepared from HEK 293 cells as described previously (31) . Double-stranded oligonucleotides used in gel mobility shift assays were prepared by annealing both strands of each LXR response element (LXRE) of the LXRE complex in the SREBP-1c promoter (LXREa [5Ј-CAGTGACCGCCAGTAACCCCAGC-3Ј] and LXREb [5Ј-GGACGCCCG CTAGTAACCCCGGC-3Ј]), labeled with [␣-32 P]dCTP by Klenow enzyme, and purified on Sephadex G50 columns. The labeled probes (3,000 to 10,000 cpm) were incubated with nuclear extracts (3 g) in a mixture (20 l) containing 10 mM Tris-HCl (pH 7.6), 50 mM KCl, 0.05 mM EDTA, 2.5 mM MgCl 2 , 8.5% glycerol, 1 mM dithiothreitol, poly(dI-dC) at 0.5 g/ml, 0.1% Triton X-100, and nonfat milk at 1 mg/ml for 30 min on ice. The DNA-protein complexes were resolved on a 4.6% polyacrylamide gel at 140 V for 1 h at 4°C. Gels were dried and exposed to a BAS2000 filter with BAStation software (Fuji Photo Film Co., Ltd.). For competition experiments, at least a 100-fold molar excess of unlabeled DNA relative to labeled DNA was added to the reaction mixture before addition of the labeled probe. In the supershift experiments, the gel shift reactions were first incubated for 1 h with 2 to 10 g of polyclonal antibodies against LXR␣ and -␤ or RXR␣ on ice.
Nuclear extract preparation and immunoblot analysis. Nuclear extracts from HepG2 cells were prepared as described previously (33) . The samples of 30 g of nuclear protein were subjected to immunoblot analysis with mouse immunoglobulin G (IgG) against human SREBP1 (30) or rabbit IgG against human SREBP1c and SREBP2 (32, 33) , followed by horseradish peroxidase-linked mouse or rabbit IgG and the ECL kit (Amersham Pharmacia Biotech).
Total RNA preparation and blot hybridization with cDNA probes. Total RNA was extracted from mouse livers, adipose tissues, and HepG2 cells using TRIZOL Reagent (Life Technologies, Inc.). Equal aliquots of total RNA from mice in each group were pooled (total, 10 g), subjected to formalin-denatured agarose electrophoresis, and transferred to nylon membrane (Hybond N; Amersham Pharmacia Biotech). Blot hybridization was performed with the cDNA probes labeled with [␣- 32 P]CTP (6,000 Ci/mmol) using the Megaprime DNA Labeling System (Amersham Pharmacia Biotech). The cDNA probes for mouse LXRs were prepared by digesting the cloned full-length LXR cDNAs (CMV-LXR␣ and -␤) with SalI and with EcoRI and NotI, respectively. The cDNA probes for human SREBP1, human SREBP2, human fatty acid synthase (FAS), and human acidic ribosomal phosphoprotein P0 (36B4) were prepared as pre-viously described (33) . The resulting bands were visualized by exposure to BAS2000 filters with BAStation software (Fuji Photo Film Co., Ltd.).
RESULTS
Our previous promoter analysis of the SREBP-1c gene 5Ј flanking region identified an SRE complex which confers an autoloop response to nuclear SREBPs and another upstream region which was induced by the presence of oxysterols (1; see Fig. 4 ). The presence of two regions with opposing sterol regulation makes SREBP-1c gene expression very complex. The initial goal of this study was to isolate transcription factors that activate SREBP-1c expression. We used an expression cloning strategy of placing the luciferase gene containing 2.6 kb of the 5Ј flanking region of the mouse SREBP-1c promoter in reporter gene assays. We previously observed that adipose tissues from SREBP-1 knockout mice highly expressed the aberrant SREBP-1c mRNA from the intact promoter of the disrupted SREBP-1c gene (33) . Therefore, we assumed that these tissues might also abundantly express the transcription factors we were seeking. From mRNAs of these tissues, we constructed an expression cDNA library under the CMV promoter. Screening was performed using luciferase assays after the cotransfection of subpools of the library and the SREBP-1c promoter luciferase reporter gene into 293 cells. Figure 1 shows a representative result of the initial screening of subpools of the library. We screened roughly 210,000 clones and picked up six positive subpools of 1,500 clones that exhibited twoto threefold increases in luciferase activity of the SREBP-1c promoter reporter compared to background levels. After several rounds of screening, six single clones were isolated from these subpools. Each of these isolated clones increased the luciferase activity 10-to 20-fold above the background. DNA sequencing revealed that three of these six clones were LXR␣ and the remaining three were LXR␤. No other clones were identified in this system. Both LXR␣ and -␤ clones contained full-length cDNAs, were assumed to express their complete respective proteins in the assays, and were designated pCMV-LXR␣ and -␤, respectively.
From a standpoint of nutritional regulation of these genes, we examined the expression of LXR␣ and -␤ in lipogenic organs, a location where the expression of SREBP-1c is suppressed by fasting and highly upregulated by refeeding. As shown in Fig. 2 , both LXR␣ and -␤ were highly expressed in both livers and adipose tissues; however, the mRNA levels were not markedly changed by these dietary manipulations. Thus, expressions of LXRs in the lipogenic organs were not subjected to the nutritional change at fasting and refeeding, unlike SREBP-1c and peroxisome proliferator-activated receptor ␣.
Studies were next focused on the effects of LXR␣ and -␤ on the SREBP-1c promoter. As an initial step, we tested the dose-dependent effects of LXR␣ and -␤ on the transcriptional activity of the SREBP-1c promoter (Fig. 3, left panel) . Expression of both LXR␣ and -␤ resulted in a dose-dependent increase in the luciferase activity of the 2.6-kb SREBP-1c promoter in the range of 0.03 to 1 g of DNA. SREBP-1c promoter activity was also induced by addition of 22(R)-HC, a well-established ligand for LXRs, to the medium in transfection studies with HEK 293 cells (Fig. 3, right panel) . A marked dose-dependent increase in the luciferase activities was observed at 22(R)-HC concentrations between 1 and 10 M, a dose range commonly used for activation of LXR. These data suggest that either the endogenous LXR␣ or -␤, or both, in the transfected cells was activated by 22(R)-HC and was able to induce SREBP-1c promoter activity. 25-HC was a significant, but much weaker, activator, whereas cholesterol was essentially inactive. To evaluate the effect of free cholesterol, different doses of cholesterol were added to cells cultured in delipidated serum and the luciferase activity was measured. Up to 10 M cholesterol did not activate the SREBP-1c promoter; however, 30 M cholesterol slightly increased the luciferase activity (data not shown). These results are consistent with the FIG. 1. Screening of an SREBP-1 knockout mouse adipose tissue expression library to identify cDNA clones which activate the SREBP-1c promoter. An expression cDNA library from the adipose tissues of SREBP-1-null mice was constructed as described in Materials and Methods. A luciferase reporter gene containing the mouse SREBP-1c promoter (2.6 kb), pBP1c2600-Luc, and each subpool containing approximately 1,500 cDNA clones were cotransfected into HEK 293 cells with pSV-␤gal as a reference plasmid. Luciferase activity was measured and normalized by ␤-galactosidase activity. After several rounds of screening, six positive single clones were isolated from the library (three LXR␣ and three LXR␤). A representative result from the initial screening is shown.
FIG. 2. Northern blot analysis of
LXRs from livers and white adipose tissues (WAT) from mice fasted and refed. Total RNA was prepared and pooled (10 g) equally from either livers or adipose tissues of normal mice fasted (F) or refed (R) after fasting as described previously (41), blotted to a nylon membrane, and hybridized with the indicated cDNA probes. A cDNA probe for 36B4 (acidic ribosomal phosphoprotein P0) was used as a loading control.
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To identify the element in the SREBP-1c promoter that was responsible for LXR activation, we compared the LXR activation of the luciferase constructs with different sizes of the SREBP-1c promoter. Our previous study identified the sterol-inducible region between bp Ϫ550 and Ϫ90 (1; Fig. 4 ). Since LXR has been shown to be activated by sterols (15, 16, 22) , 25-HC, and cholesterol, compounds commonly used for a sterol-suppressive condition, it was reasonable to assume that this region could be an LXR activation site. Initial luciferase assays with BP1c2600-Luc, BP1c550-Luc, and BP1c90-Luc demonstrated that LXR activation was observed with BP1c2600 and BP1c550, but not with BP1c90, confirming the presence of an LXR activation site between bp Ϫ550 and Ϫ90 (Fig. 4) . Figure 5 shows luciferase activities after LXR␣ or -␤ coexpression in sequential-deletioncontaining SREBP-1c promoter constructs assembled to identify the LXR activation sites. In the sterol-inducible region, we found a sequence at bp Ϫ377 to Ϫ362 which was similar to the LXRE (GGTCCAGGCAAGTTCT) (1) . However, as shown in Fig. 5B , deletion of this sequence did not affect the LXR activation of the SREBP-1c promoter, indicating that this sequence was not involved. In contrast, considerable reduction in both LXR␣ and -␤ activation was observed when two regions, bp Ϫ249 to Ϫ187 and bp Ϫ186 to Ϫ148 were deleted. Loss of both regions essentially abolished the LXR activation, suggesting that these regions are crucial. As depicted in Fig. 5A , each candidate region contains a DR-4 sequence which was similar to the inverted LXRE. While this report was being prepared; a detailed promoter analysis of the ABC1 gene containing a new LXR-binding sequence in an inverted orientation was reported (6; Fig. 5A ). LXREa, an upstream element of the two LXREs in the SREBP-1c promoter closely matched this new sequence (9 out of 10 bases in the two direct repeats), and the other (LXREb) also showed significant similarity (7 out of 10 bases).
To show direct binding of LXRs to LXREa or LXREb, gel mobility shift assays were performed (Fig. 6) . A labeled LXREa or LXREb probe was shifted by incubation of nuclear extracts from cells in which LXR␣ or -␤ and RXR were overexpressed. Coexpression of RXR was required for the binding of LXRs to LXREs (data not shown). Preincubation of the reaction mixture with antibodies against LXR␣ and -␤ or RXR␣ caused a supershift of the LXR-RXR DNA complex, confirming the specific binding of LXR-RXR to these LXREs, although the shifts caused by these antibodies were partial, as previously described (23) . Competition assays suggest that LXREb has a slightly higher affinity for LXRs than does LXREa.
Based upon these data, we tentatively designated the region between bp Ϫ249 and bp Ϫ149 containing the two LXR-binding sites an LXRE complex (Fig. 6B ). An LXRE complex enhancer construct (pLXRE-Luc) in which the LXRE complex was inserted upstream of simian virus 40 promoter luciferase gene (pGL2 promoter vector) was prepared and tested for activation by LXR. Dose dependency and the effect of 22(R)-HC were essentially the same as those observed in the 2.6-kb SREBP-1c promoter construct (Fig. 7) , indicating that this region basically represents the whole response of the SREBP-1c promoter to LXR. Mutation analysis was also performed on these two LXREs using the LXRE complex enhancer construct (pLXRE-Luc) (Fig.  5B) . Mutation of either LXREa or LXREb significantly reduced the induction of luciferase activity by LXR expression. Mutation of both LXREs essentially abolished the effect of LXR. These results confirmed the role of both LXREs in LXR activation of the SREBP-1c promoter, although LXREb seemed relatively more important.
Since LXRs are obligated to heterodimerize with RXR in order to activate their target genes, the effects of coexpression of RXR and its ligand on LXR activation of LXRE-Luc were investigated (Fig. 8) . Addition of 22(R)-HC or 9CRA to the medium caused some increase in this enhancer activity, and both genic gene, but not SREBP-2 gene mRNA (Fig. 10) . HepG2 cells were transfected with the FAS promoter-luciferase gene to evaluate the transcriptional activity of LXR-induced nuclear SREBP-1c. As shown in Fig. 11 , addition of 22(R)-HC and 9CRA to the medium caused only a marginal increase in the FAS-Luc activity. However, coexpression of LXR␣ and -␤ with these ligands markedly increased the luciferase activity up to one-third of the level of activation caused by by direct overexpression of nuclear SREBP-1c (CMV-SREBP1c). This induction was significant even in the presence of 25-HC and cholesterol, a condition that suppresses endogenous SREBP-1a and -2 activities by inhibiting the sterol-regulatory cleavage of SREBPs. These data demonstrate that LXR-RXR induction of SREBP-1c can potentially increase its target gene expression regardless of sterol regulation.
DISCUSSION
The current studies clearly demonstrate that LXR-RXR activates SREBP-1c expression by binding to newly identified LXR-binding sites in the SREBP-1c promoter. In our expression cloning system from mouse adipose tissue with a reporter gene containing the native SREBP-1c promoter (2.6 kb), we could isolate only LXR␣ and -␤, suggesting that LXRs are abundant and potent activators of the SREBP-1c promoter. The LXRE complex, composed of two inverted DR4-type LXREs at approximately a 30-bp interval. Both binding sites contributed to activation of the SREBP-1c promoter. The promoters of the LXR target genes which have been analyzed to date contain only a single LXRE (6, 22, 23) . The presence of two copies of LXREs in the LXRE complex could make the response of the SREBP-1c gene to LXR-RXR strong.
The importance of LXR for expression of SREBP-1 has already been recognized in a previous report on LXR␣ knockout mice (25) . In the LXR␣ knockout mice, induction of cho- VOL. 21, 2001 ACTIVATION OF SREBP-1c GENE PROMOTER BY LXR-RXRlesterol 7␣-hydroxylase was impaired, resulting in hepatic accumulation of cholesterol when dietary cholesterol was consumed. One intriguing observation in the livers of these mice was a considerable reduction of SREBP-1 mRNA and protein levels, leading to a decrease in some lipogenic enzyme mRNA levels. Our current data on activation of SREBP-1c expression by LXRs can explain this observation. Furthermore, the LXR␣-deficient mouse data suggest that LXR␣ is an important regulator of SREBP-1c expression in the liver because LXR␤ cannot entirely compensate for the absence of LXR␣. It would be interesting to see a tissue survey of SREBP-1c expression in LXR␣-and -␤-deficient mice, as well as mice doubly deficient in both LXRs, to estimate the contribution of these two factors to SREBP-1c expression in different tissues. It is intriguing to speculate about the physiological significance of SREBP-1c induction by LXR. Recent studies identifying the genes for 7␣-cholesterol hydroxylase (25) , cholesterol ester transfer protein (23) , and ABC1 (6, 26) as target genes of LXRs suggest that LXR-RXR seems to play an important role in cellular adaptation to the accumulation of excess cholesterol by enhancing catabolism of cholesterol into bile acid (23, 25) or by promoting cholesterol efflux (26, 29) . SREBP-1c is a transcription factor for lipogenesis, and its induction should cause an increase in the synthesis of fatty acids. These fatty acids can then provide a source for acyl residues to produce cholesterol esters from cholesterol and protect cells from the cytotoxic effect of free cholesterol accumulation (Fig. 12A) . On the other hand, in cells with a cholesterol overload leading to activation of the cholesterol efflux system, cholesterol synthesis is negatively regulated through suppression of cleavage of SREBPs by a sterol-sensing and regulation system consisting of SCAP and site 1 protease. This reduction in SREBP cleavage activity should counterbalance the effect of LXR induction of the SREBP-1c precursor protein. However, our recent findings suggest that cleavage of SREBP-1c is not as tightly regulated by sterols as is that of SREBP-2 in liver cell lines, suggesting that nuclear SREBP-1c has a chance to liberate its nuclear active form into the nucleus even in a state of cholesterol accumulation (10) . This is supported by our current finding that transfection of LXR-RXR into HepG2 cells with addition of 22(R)-HC increased the amount of endogenous nuclear SREBP-1c and the resultant luciferase activity of its downstream gene even in a sterolsuppressed condition (Fig. 11) . Taken together, these data allow us to hypothesize that LXR-RXR activation of SREBP1c might have a physiologic function situations of excess cellular cholesterol accumulation (Fig. 12A) . While this would result in an overall decrease in the cleavage of SREBPs, the lack of complete control of sterols over the SREBP-1c precursor, combined with the ability of LXRs to simulate SREBP-1c expression, would ensure that a certain amount of nuclear SREBP-1c was available to stimulate the production of fatty acids, presumably to protect cells from the deposition of free cholesterol to a toxic level. On the other hand, when cells are depleted of cholesterol, activation of the cleavage system will increase nuclear SREBPs, including SREBP-1c, to maintain lipogenesis even in the absence of LXR activation (Fig. 12B) . As illustrated in Fig. 12 , this multiple-complex system for SREBP-1c promoter activity links SREBP-1c expression, and thus lipogenesis, partially to sterol regulation but also to some FIG. 10 . SREBP-1, -2, and FAS mRNA levels in HepG2 cells treated with LXR or RXR ligands as measured by Northern blot analysis. HepG2 cells were incubated with the indicated ligands for LXR or RXR for 24 h. In some groups, 25-HC at 1 g/ml and cholesterol at 10 g/ml were added to the medium to suppress the sterolregulatory cleavage activity of SREBPs (sterol-suppressed condition). Total RNA was prepared and pooled (10 g) equally from HepG2 cells, blotted to a nylon membrane, and then hybridized with the indicated cDNA probes. The values below the bands refer to relative fold changes in mRNA levels normalized relative to the 36B4 signal. Lanes: 1, ethanol; 2, 22(R)-HC; 3, 9CRA; 4, 22(R)-HC plus 9CRA; 5, ethanol in a sterol-suppressed condition; 6, 22(R)-HC plus 9CRA in a sterol-suppressed condition. A cDNA probe for 36B4 (acidic ribosomal phosphoprotein P0) was used as a loading control. FIG. 11 . Activation of the FAS promoter by LXRs and their ligands. A luciferase reporter construct containing the rat FAS promoter (31) and reference plasmid pSV-␤gal with empty plasmid pCMV7 or expression plasmids pCMV-LXR and pRXR were transfected into HepG2 cells. After the transfection, ligands for LXR and RXR or ethanol (used as a negative control) was added to the cells, followed by a 24-h incubation in the medium with 10% fetal bovine serum. In some sets, 25-HC at 1 g/ml and cholesterol at 10 g/ml were also added to the medium to suppress the sterol-regulatory cleavage activity of SREBPs (sterol-suppressed condition). Luciferase activity was measured and normalized to ␤-galactosidase activity. Fold induction (means Ϯ standard deviations) by LXRs is shown. pCMVnSREBP-1c, an expression plasmid of human nuclear SREBP-1c was used as a positive control for FAS promoter activation (BP-1c). L␣ϩR, LXR␣ plus RXR; 22ϩ9, 22(R)-HC plus 9CRA. levels of control irrespective of sterols. Considering that the list of SREBP-1 target genes seems to be expanding, it is also possible that LXR activation of SREBP-1c could activate unknown target genes to cause as yet unidentified physiological consequences.
Oxysterol receptors are involved in cholesterol catabolism (activation of 7␣-cholesterol hydroxylase for bile acid synthesis and ABC1 for the reverse cholesterol transporter [6, 25, 26] ), with the ligands 22(R)-HC, 24(S)-HC, and 24,25(S)-epoxycholesterol demonstrating the highest affinities for LXRs (15, 16, 22) . In contrast, 25-HC is the most potent known suppressor of SREBP-2 in the regulation of cholesterol synthesis (42) . The cause for different affinities of oxysterols in the regulation of cholesterol catabolism and synthesis in response to the same cholesterol accumulation is currently unknown. Further investigation to seek out other ligands for LXR could lead to the discovery of a common and real physiological signaling molecule for cholesterol metabolism. Meanwhile, our current study suggests that the expression level of LXRs, in addition to their ligand concentrations, can be another potential method for the regulation of LXR target genes.
It is noteworthy that in some experiments, RXR and its ligand exhibited an effect similar to or even higher than those of LXRs and their ligands on SREBP-1c activation. Since RXR forms heterodimers with different nuclear receptors such as retinoic acid receptor, peroxisome proliferator-activated receptors, farnesoid X receptor, and some orphan receptors, the effect of RXR activation should be diverse. Therefore, it was also possible that an alternative heterodimerizing nuclear receptor might be involved in SREBP-1c activation. Tissue specificity of copartners for RXR heterodimers might be crucial for the physiological consequences of RXR manipulation. SRϭBP-1c seems to be involved in energy disturbances causing fatty liver, remnant particle production, and insulin resistance and may therefore be a therapeutic target for these fuel metabolism disorders. Together with recent reports on the activation of ABC1 as a reverse cholesterol transporter, LXR-RXR could be a useful tool with clinical application in the control of cholesterol and fuel metabolic disorders.
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